Skip to main
  1. Stocks
  2. Coherus BioSciences
  3. Forecast
CHRS

Coherus BioSciences (CHRS) Stock Forecast & Price Target

Coherus BioSciences (CHRS) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Coherus Oncology is attractive fundamentally because it combines an approved, commercial PD-1 franchise with a pipeline that could materially expand value through multiple shots on goal, led by tagmokitug in esophageal cancer and casdozokitug in liver cancer. Loqtorzi is already growing, with 3Q net revenue of $14.0M (+3% QoQ, +25% YoY), and management expects quarterly sales to rise further while the company lowers core cash burn by $6M-$7M per quarter after a ~30% headcount reduction. The thesis is strengthened by differentiated clinical data, including 1L ESCC response rates up to 89% and 1L HCC activity with a 37.9% ORR and 17.2% CR rate, which suggests the pipeline could drive meaningful long-term revenue beyond the current $179M market cap.

Bears say

Coherus Oncology is burdened by a high clinical and regulatory risk profile, because the investment case still hinges on small, interim, largely single-arm data that may not hold up in larger or randomized studies, while even a strong pooled ORR would be insufficient if the control arm performs similarly. Financially, the company remains loss-making, with a $33.3M net loss from continuing operations in 2Q26 and $183.1M in 2025, and it ended 2Q26 with $105.3M in cash and $37.2M of debt, implying only limited near-term flexibility despite management’s guidance. The outlook is further weakened by intense competition, dependence on future approvals and manufacturing/regulatory milestones, and an expected need for additional equity capital that could dilute shareholders if pipeline development continues to require funding.

Coherus BioSciences (CHRS) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Coherus BioSciences and is not a guaranteed prediction by Public.com or investment advice.

Coherus BioSciences (CHRS) Analyst Forecast & Price Prediction

Get the latest Coherus BioSciences (CHRS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Coherus BioSciences (CHRS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Coherus BioSciences (CHRS) Forecast

Analysts have given Coherus BioSciences (CHRS) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Coherus BioSciences (CHRS) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Coherus BioSciences (CHRS)


Coherus BioSciences (CHRS) Analyst Forecast & Price Prediction

Get the latest Coherus BioSciences (CHRS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Coherus BioSciences (CHRS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CHRS stock data and trends